PGDx elio™ plasma focus

A targeted liquid biopsy assay for research

Biomarker analysis and discovery for cancer research

The PGDx elio plasma focus kit evaluates a targeted panel of 33 well-characterized cancer genes using circulating tumor DNA (ctDNA). Get rapid, accurate results from low yielding plasma specimens from patients with solid tumors.

Product features

- **Reliable:** Highly accurate somatic mutation identification
- **Curated:** Identifies variants in 33 full coding genes that have approved therapies or are in professional guidelines for oncology
- **Fast:** Results generated in five days* via streamlined workflow and automated bioinformatics that enable high-throughput runs
- **Accessible:** In-house testing with complete data ownership
- **Global:** Available to clinical research labs around the world

* Kitted workflow plus pipeline output. Not inclusive of DNA extraction and downstream processing

Development

- **Pan solid tumor:** Plasma analysis for in-house solid tumor biomarker analysis and discovery
- **Proven:** Results concordant to other NGS assays across variants of clinical significance
- **Reliable:** Robustly tested in clinical trials to ensure highly accurate results
- **Trustworthy:** 30,000x sequencing coverage

PGDx elio plasma focus identifies somatic mutations with high accuracy and sensitivity



Simplify your workflow

From extracted circulating cell free DNA (cfDNA) to curated analytical reports, PGDx optimizes your workflow and outcomes. PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab with timely and trustworthy results. High-quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.



labcorp | Oncology

A sample-to-answer liquid biopsy solution

PGDx elio plasma focus is an in-house pan solid tumor NGS liquid biopsy assay that identifies key genomic alterations and guideline-supported biomarkers with high accuracy and sensitivity down to 0.1% variant allele frequency (VAF). It features proprietary methods for detecting microsatellite instability (MSI) as well as complex structural alterations and amplifications.

- **Simplify** sampling with low specimen input for high-impact genes
- **Streamline** genomic analysis with robust, automated bioinformatics
- **Access** rapid liquid biopsy-based tumor insights
- **Facilitate** large-scale studies with liquid biopsy format

Gene panel

Proprietary method for MSI

SNVs and indels (33 genes)										
AKT1	ARID1A	BRCA1	CCND1	CSF1R	EZH2	HRAS	MET	NTRK1	POLD1	RET
ALK	ATM	BRCA2	CD274	EGFR	FGFR1	KIT	MYC	PDGFRA	POLE	ROS1
APC	BRAF	BRIP1	CDH1	ERBB2	FGFR2	KRAS	NRAS	PIK3CA	RAF1	TP53
Amplifications (8 genes)										
CCND1	CD274	EGFR	ERBB2	FGFR2	KIT	MET	MYC			
Translocations (5 genes)										
ALK	FGFR2	NTRK1	RET	ROS1						

Assay specifications

Sample type	Plasma cfDNA (Streck or EDTA)
cfDNA input amount	25 ng recommended, down to 10 ng
Sequencing platform	Illumina NextSeq 550/550Dx
Read length	2 x 150 bp
Cases per sequencing run	8 samples (7 cases + 1 external control)

Analytical performance

Variant	Reportable range	Analytical sensitivity (LOD95)	Analytical specificity
Actionable SNVs/indels	>0.1% VAF	> 0.34% VAF	99.98%
Nonactionable SNVs/indels	≥0.5% VAF	> 0.57% VAF	99.99%
All Translocations	3 fusion reads	0.41% FRF*	100%
All Amplifications	≥1.2-fold	≥ 1.3-fold	100%

*FRF, fusion read fraction

Learn more about PGDx elio plasma focus at **personalgenome.com**
or scan the QR code

labcorp | Oncology